Measurement of quality of life in schizophrenia: a comparison of two scales. by Kusel, Y, Laugharne, R, Perrington, S, McKendrick, J, Stephenson, D, Stockton-Henderson, J, Barley, M, McCaul, R, Burns, T

Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. by Burns, T, Christova, L, Cooper, S, Harrison, G, McKendrick, J, Laugharne, R, Obuaya, T, McCreadie, R, O'Brien, S, Perrington, S, Stephenson, D

The impact of intellectual functioning on symptoms and service use in schizophrenia. by Chaplin, R, Barley, M, Cooper, S, Kusel, Y, McKendrick, J, Stephenson, D, Obuaya, T, Stockton-Henderson, J, O'Brien, L, Burns, T

Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer by Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H

The dental health of people with schizophrenia. by McCreadie, R, Stevens, H, Henderson, J, Hall, D, McCaul, R, Filik, R, Young, G, Sutch, G, Kanagaratnam, G, Perrington, S, McKendrick, J, Stephenson, D, Burns, T

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. by Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L